Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

NCT04821765 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Esophagus Cancer
Chemoradiotherapy
Oligometastatic Disease
Immunotherapy

Interventions

DRUG: PD-1 antibody
RADIATION: Chemoradiation
DRUG: Albumin-Bound Paclitaxel
DRUG: Cisplatin

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences